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Abstract
Background: The innate immune receptor RIG-I detects viral RNA within the cytosol of infected cells. Activation of
RIG-I leads to the induction of antiviral cytokines, in particular type I interferon, the inhibition of a T(H)17 response as
well as to the suppression of tumor growth. Therefore, RIG-I is a promising drug target for the treatment of cancer as
well as multiple sclerosis. A specific ligand for RIG-I is currently in preclinical testing. The first-in-human trial will need to
be carefully designed to avoid an overshooting cytokine response. Therefore, the ResI study was set up to analyze the
human immune response to standard treatment with recombinant interferon-beta to establish biomarkers for safety
and efficacy of the upcoming first-in-human trial investigating the RIG-I ligand.
Methods/Design: ResI is a single center, prospective, open label, non-randomized phase I clinical trial. Three different
cohorts (20 healthy volunteers, 20 patients with RRMS and ongoing interferon-beta treatment and 10 patients starting
on interferon-beta) will receive standard interferon-beta-1a therapy for nine days. The study will be conducted
according to the principles of the german medicinal products act, ICH-GCP, and the Declaration of Helsinki
on the phase I unit of the Institute of Clinical Chemistry and Clinical Pharmacology and in the Department of
Neurology, both University Hospital Bonn. Interferon-beta-induced cytokine levels, surface marker on immune
cells, mRNA- and miRNA-expression as well as psychometric response will be investigated as target variables.
Discussion: The ResI study will assess biomarkers in response to interferon-β treatment to guide the dose steps
within the first-in-human trial with a newly developed RIG-I ligand. Thus, ResI is a biomarker study to enhance the
safety of the clinical development of a first-in-class compound. The data can additionally be used for the development
of other therapies based on type I interferon induction such as TLR ligands. Moreover, it will help to understand the
interferon-beta induced immune response in a controlled in vivo setting in the human system.
Trial registration: clinicaltrials.gov ID NCT02364986
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Background
Retinoic acid inducible gene-I (RIG-I) is a pattern recog-
nition receptor (PRR) of the innate immune system,
broadly expressed in immune - but also in non-immune
cells, including tumor cells [1–3]. RIG-I is a sensor for
pathogenic RNA, detecting 5’-triphosphorylated RNA
(3pRNA) in the cytosol of infected cells [4, 5], crucially
important to protect from different RNA viruses [2, 6].
Activation of RIG-I leads to a broad antiviral immune
response, including strong induction of type I interferon
(IFN), to eradicate the invading pathogen. A potent
benefit of therapeutic activation of RIG-I was described
recently in different indications: i) 3pRNA suppresses
tumor growth by triggering apoptosis specifically in
tumor but not in non-malignant cells as well as by indu-
cing an anti-tumor immune response, including type I
IFN induction and NK cell activation [7–10]. ii) Activa-
tion of RIG-I inhibits the viral replication and is there-
fore protective in viral diseases such as Hepatitis B [11]
and influenza infection (unpublished data). iii) Activa-
tion of RIG-I in mice with induced experimental auto-
immune encephalomyelitis, the animal model for MS,
significantly ameliorates autoimmune inflammation, de-
creases demyelination and improves the clinical outcome
by repressing the maintenance and expansion of T(H)1
and T(H)17 cells [12]. As in all these indications an
unmet therapeutic need exists, triggering of RIG-I by a
synthetic short 3pRNA-ligand is a promising new thera-
peutic approach with broad clinical implication [1]. A
specific RNA ligand for RIG-I is currently under preclin-
ical evaluation. Even though we identified relevant ani-
mal species for preclinical toxicity testing (unpublished
data) the RIG-I ligand bears characteristics making in-
creased caution in the first-in-human trial necessary as
outlined in the European Medicines Agency (EMA)
“Guideline on strategies to identify and mitigate risks for
first-in-human clinical trials with investigational medi-
cinal products” (EMEA/CHMP/SWP/28367/07): i) as
first-in-class compound it is a novel mechanism of ac-
tion, involving multiple signalling pathways [13] ii) it is
an activating mechanism and iii) the RIG-I ligand acts
on the immune system inducing the release of antiviral
and pro-inflammatory cytokines [1, 4, 5]. To minimize
the probability of a possible overshooting cytokine induc-
tion in the first-in-man phase I trial, thorough preclinical
testing needs to be performed. In addition, biomarkers
indicating activity or toxicity of RIG-I agonisation would
be of great value to safely guide the first-in-man trial.
Moreover, such biomarkers could be used as surrogate
parameter to gather first data on the potential efficacy of a
RIG-I ligand, starting in the first-in-man trial and later on
in more advanced stages of the clinical development. Type
I IFN serum level as well as the dependent immune re-
sponse will bear suitable information for dose guiding of
the RIG-I ligand since type I IFN is a key cytokine induced
by RIG-I [4, 14]. To give an orientation on a type I IFN
level that is potentially therapeutic active, the effect of
standard interferon treatment as routinely applied in mul-
tiple sclerosis can be used. As soon as the type I IFN
response induced by a certain dose of the RIG-I ligand
reaches the levels induced by standard treatment with
recombinant IFN-β, this level can be regarded as a poten-
tially effective dose. With this information the dose steps
within the phase I study can be carefully guided, side ef-
fects better monitored and there will be no need to explore
the maximal tolerable dose.
For this purpose, the ResI study was set up as a clinical
trial aiming to establish a biomarker for the safety and
efficacy of the RIG-I ligand, a novel therapeutic entity
currently in preclinical testings. Since studies of the
RIG-I ligand will start in healthy volunteers and will be
continued in MS patients both populations are included
in this study as they could show significant differences
in response to IFN-β. Additionally, this comprehensive,
prospective analysis of the IFN-β dependent immune ac-
tivation and changes in miRNA expression in this con-
trolled setting will help to understand the physiological
response to IFN-β in healthy volunteers and in MS
patients.
Methods/Design
ResI is a single center, prospective, open label, non-
randomized phase I clinical trial. Three different co-
horts (healthy volunteers, patients with RRMS and
ongoing IFN-β treatment and patients with RRMS
starting on IFN-β treatment) will receive three applica-
tions of standard IFN-β therapy for nine days. As a
comparison between pre- and post-treatment is per-
formed, no placebo group is planned. The study will be
conducted according to the principles of the german
medicinal products act, ICH-GCP, and the Declaration
of Helsinki on the phase I unit of the Institute of Clinical
Chemistry and Clinical Pharmacology and in the Depart-
ment of Neurology, both University Hospital Bonn. The
local ethics committee and the German competent au-
thorities (Federal Institute for Drugs and Medical Devices)
already approved this study. The Clinical Study Core Unit
will perform the clinical procedures, monitoring, safety
management, data management, and data analysis of the
study. The Institute of Clinical Chemistry and Clinical
Pharmcology, that includes the central laboratory of the
University Hospital Bonn will perform the routine as well
as experimental laboratory analysis.
Primary objective
The primary objective of this phase I trial is to deter-
mine IFN-β protein level as well as IFN-β-dependent
mRNA and protein expression in healthy volunteers and
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in RRMS patients continuing or starting on IFN-β treat-
ment (including CXCL10, MxA, RIG-I).
Secondary objectives
Secondary objectives of this trial are the analysis of the
miRNA- and gene-expression pattern in response to re-
combinant IFN-β in peripheral blood mononuclear cells
and serum of healthy volunteers as well as RRMS pa-
tients, the comparison of the response to IFN-β between
healthy volunteers, patients with RRMS naïve to IFN-β
treatment and RRMS-patients with established IFN-β
treatment, correlation of side effects of IFN-β treatment
with immune- or miRNA-response to IFN-β. Potential
central nervous adverse drug effects such as emotional
changes associated with IFN-β treatment (depression,
anxiety, impulsivity) will be assessed by psychometric
testings and noninvasive neuroimaging techniques.
Inclusion criteria
Three different cohorts will be studied: 1.) Healthy
volunteers naïve for IFN-β treatment. 2.) patients with
relapsing-remitting MS (RRMS) according to McDonald's
criteria and baseline expanded disability status scale
(EDSS) score from 0 to 6.0 starting on IFN-β treatment
according to routine clinical criteria. 3.) Patients as
described above but already on IFN-β treatment. Add-
itional inclusion criteria applicable for all individuals in
this study: age between 18 and 65 years, adequate bone
marrow-, renal-, hepatic- and clotting-function. Male
and female patients with reproductive potential have to
use an approved contraceptive method and a negative
serum pregnancy test must be obtained prior to treat-
ment start in female patients with childbearing poten-
tial. All individuals need to have signed the informed
consent form.
Exclusion criteria
The main exclusion criteria comprise of: known allergy
or hypersensitivity to IFN-β or ingredients of the injec-
tion solution; condition or disease which at the investi-
gator’s discretion do not fit with the study; known or
persistent abuse of medication, drugs or alcohol; current
use of cortisone preparation; subjects with reproductive
potential who do not accept to use contraception during
the trial and 3 months thereafter or women who are
pregnant or breast-feeding; prior malignancy except for
adequately treated carcinoma in situ of the cervix or
non-melanoma skin cancer unless prior malignancy was
diagnosed and definitively treated at least 5 years previ-
ously with no subsequent evidence of recurrence the
subject at the discretion of the investigator; prior
chemotherapy, systemic or local treatment with DNA-
damaging and immune-modulating agents, tyrosine kin-
ase inhibitors or anti-angiogenic agents for any cancer;
history of major depression, suicide attempt in the past,
ongoing suicidal thoughts; history of epileptic seizures
under medical therapy with antiepileptic drugs; cardiac in-
sufficiency (NYHA III or IV) cardiomyopathy, significant
cardiac dysrhythmia, unstable or advanced ischemic heart
disease, or significant hypertension at rest (blood pres-
sure > 180/110 mmHg); HIV, Hepatitis B or C infection or
any relevant infectious disease which might interfere with
the study procedures and results (at the discretion of the
investigator).
Therapy
Three different cohorts will be treated in this study:
healthy volunteers, patients with RRMS and ongoing
IFN-β treatment and patients with RRMS starting on
IFN-β treatment. Patients and healthy volunteers will re-
ceive three doses of 44 μg open-label Interferon-β-1a
(Rebif®) within nine days as recommended in the stand-
ard treatment schedule. MS patients already on IFN-β
treatment will only receive one dose of IFN-β while in-
cluded in this study. Dose modification or adjustments
for either group are not intended by the trial protocol.
After the study is finished MS patients will be treated at
the discretion of the responsible physician.
At or before the screening visit, each patient has to
provide written informed consent to the study. The
screening consists of reviewing inclusion and exclusion
criteria, demographic variables, medical history, concomi-
tant medication, physical and neurological examination
and vital signs, electrocardiogram (ECG) and laboratory
tests are obtained by a study nurse and the treating phys-
ician. MRI, EDSS scoring and psychometric tests are per-
formed. Laboratory tests include complete blood count,
serum chemistry, coagulation, drug screening, pregnancy
test and urine analysis.
At baseline visit vital signs and ECG as well as the
occurrence of adverse events and changes of the con-
comitant medication are documented. Screening and
baseline visit are performed within 14 days. Then IFN-
β-1a treatment is started and blood for the analysis of
cytokine serum levels, miRNA- and mRNA-expression
as well as experimental immune evaluation is collected
at five different times within 24 h. Thereupon, the study
is finished for MS patients that have been already on
IFN-β treatment. Healthy volunteers as well as MS pa-
tients that have been started on IFN-β will continue
with study visits at days 3, 5 and 8 with documentation
of adverse events and concomitant medication and collec-
tion of further blood samples for analysis of immune
activation. At day nine healthy volunteers as well as MS
patients will have the final visit with the same assessments
as described for the screening and baseline visit, including
magnetic resonance imaging (MRI) assessment. Additional,
blood for analysis of immune activation is collected.
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Magnetic resonance imaging
To characterize neurobiological correlates of the action
of IFN-β, changes in base perfusion levels, in limbic re-
activity to emotionally laden stimuli, in the neural re-
sponse to potential rewards, and their association with
psychometric parameters will be assessed in healthy
volunteers through noninvasive neuroimaging techniques.
All MRI scans are performed according to a standardized
MRI protocol and will be assessed centrally. MRI scans of
the brain will be performed only in the healthy volunteers
at the screening and at the final visit. Functional neuroim-
aging of limbic reactivity will be performed to analyze
both emotional reactivity and the capacity of participants
to down-regulate it.
Statistical analysis
The sample size is set on 20 healthy volunteers and 20
patients with established IFN-β treatment and 10 MS
patients naïve to IFN-β treatment. Since this is a study
to gain information about the distribution of the expres-
sion values in these patients, this sample size is not
based on statistical considerations.
Primary target variables of the study is the estima-
tion of changes in serum level of type I IFN and type I
IFN-dependent proteins (e.g. CXCL10) as well as of
changes in mRNA expression of type I IFN-dependent
genes (e.g. CXCL10, MxA and RIG-I) after a dose of
IFN-β treatment in healthy volunteers and in patients
with RRMS. For this purpose, the median of the levels
will be calculated separately for the two study groups.
95 % confidence intervals for the medians will be calcu-
lated using bootstrap. As additional descriptive parame-
ters mean, standard deviation, minimum, maximum and
the quartiles of the distribution will be calculated for
each group and variable. A comparison of the expression
levels between patients and controls will be performed
with a two-sided Mann–Whitney-Wilcoxon test. These
tests are regarded as descriptive analysis, their result are
reported as p-values.
Discussion
Mimicking a viral infection by activating pattern recog-
nition receptors (PRR) of the innate immune system is
an interesting therapeutic approach, tested for a variety
of indications [1, 15, 16]. Apart from the toll-like recep-
tor family, the retinoic acid inducible gene-I (RIG-I) is a
particular promising candidate for this strategy. RIG-I is
suggested as drug target in a broad range of indications
including viral infections, cancer and autoimmune dis-
ease such as multiple sclerosis [1]. RIG-I is ubiquitously
expressed in non-malignant but also malignant cells and
leads not only to the release of antiviral cytokines (e.g.
type I IFN) and NK cell activation but also to apoptosis
induction in cancer but not in non-malignant cells [7–11].
Moreover, RIG-I activation can suppress a T(H)17 re-
sponse in vivo [12]. Thus, the immediate and comprehen-
sive immune response orchestrated by RIG-I seems to be
of great potential in a variety of diseases with a still unmet
medical need. But it needs to be taken into account that
all these mechanisms of actions are not only beneficial but
can also cause side effects depending on the dose.
Therefore, the immune activation by RIG-I needs to be
sufficiently understood and well balanced. The disas-
trous outcome of the TeGenero trial unintentionally
demonstrated the consequences of an underestimated
activating immune effect leading to a cytokine storm
[17]. As a consequence the EMA released a guideline
describing risk factors to be considered before starting
a first-in-human phase I trial (EMEA/CHMP/SWP/
28367/07). As the RIG-I ligand represents a new mode
of action, is activating in nature and turns on different
immune pathways, this therapeutic approach has mul-
tiple aspects of high risk compounds. Therefore, the
preclinical data need to be gathere carefully and scien-
tifically driven to obtain a comprehensive understand-
ing of the potential outcomes of the RIG-I ligand
administration. To further reduce the risk of the up-
coming phase I studies with the new RIG-I ligand, we
decided to design a clinical study to add human in vivo
data that are suitable to function as a biomarker for the
immune activation induced by RIG-I. To this end, we
will comprehensively measure the immune response in-
duced by standard treatment with recombinant IFN-β,
including protein and mRNA expression of known
IFN-β dependent genes (e.g. CXCL10, MxA, RIG-I),
miRNA expression pattern, genome wide mRNA ex-
pression. In the subsequent phase I studies with the
RIG-I ligand these information will be used to judge
whether the induced type I IFN is below or above
standard treatment with recombinant IFN-β. In addition,
as emotional changes are described for type I IFN [18–21],
we will perform functional MRI scans to screen for early
effects in order to learn how this side effect can be detected
early upon exposure to a RIG-I ligand. Therefore, the study
presented here will provide crucial data to safely guide the
application of the RIG-I ligand. To rule out differences in
the response to IFN-β we will include both healthy volun-
teers as the first population within the clinical testing being
exposed to the RIG-I ligand as well as patients with
relapsing-remitting multiple sclerosis as patients meant to
be treated with the RIG-I ligand later in development. Al-
though numerous effects of type I IFN on the immune sys-
tem are well established since decades, the results from the
literature cannot be used here for different reasons: data
obtained in animal or in vitro systems do not necessarily
reflect the in vivo situation in humans, the complete set of
read outs were not investigated in a single comprehensive
study, it is unclear how repeatable the assays are that were
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used, and studies were often done in patients but not
healthy volunteers with confounding factors such as
concomitant medications. In addition, potential adverse
neurological drug effects have to be assessed in vivo in
humans without confounding factors of neurological
disease symptoms. Therefore, a lot of emphasis is laid
on the quantitative measurement of potential emotional
or cognitive changes due to the exposure to IFN-β in
healthy humans using MRI techniques. To be technic-
ally able to transfer the results in the biomarker study
to the phase I studies with the RIG-I ligand, the main
read outs used here (ELISA and qPCR) will be validated
on repeatability, precision, pre-assay effects, dilution
linearity and adequate controls and standards will be
generated and included that can be used for compari-
son in future studies. Nevertheless, information ob-
tained here will bear certain limitations: activation of
RIG-I leads to a profound induction of type I IFN but
also induces additional pathways and cytokines such as
pro-inflammatory cytokines (e.g. IL-6) and IFN-γ (un-
published data) not mimicked by application of IFN-β
alone. Additionally, the time course of type I IFN in-
duction caused by activation of RIG-I is not necessarily
mirrored by application of the recombinant protein.
Therefore, the results of this biomarker study need to
be interpreted in connection with the complete preclin-
ical program and are not meant to substitute for it. But
taking these limitations into account, this study is a
rare, maybe unique approach to define biomarkers in
the human system in vivo that increases the safety of
the clinical development of a drug before the actual
compound is given the first time to healthy subjects.
The data obtained here can be additionally used to
guide other treatments also involving induction of type
I IFN, such as ligands for TLR7 or 9 (as intended effect
or unwanted side effect, e.g. siRNA) [15, 16, 22, 23].
Therefore, this study proposes a way, how the safety of
a first-in-man phase I clinical trial can be enhanced in
addition to the principles outlined in the current guide-
lines of drug development. As additional benefit, this
study is suitable to find new factors being induced by
type I IFN in the human system in vivo, namely in- or
decreased miRNA, since studies investigating the ef-
fects of type I IFN in a very controlled human in vivo
system in healthy volunteers are rare.
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